Bodhi Tree Biotechnology Inc (BDTB) Cash & Equivalents (2024 - 2026)

Bodhi Tree Biotechnology (BDTB) has reported Cash & Equivalents for 3 consecutive years, with $250000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 109.18% year-over-year to $250000.0 in Q2 2026; TTM through Jun 2026 was $250000.0, a 109.18% increase from a year earlier, with the FY2025 full-year figure at $109404.0, down 57.85% from the prior year.
• Cash & Equivalents was $250000.0 for Q2 2026 at Bodhi Tree Biotechnology, roughly flat from $250000.0 in the prior quarter.
• Over five years, Cash & Equivalents peaked at $259570.0 in Q3 2024 and troughed at $109404.0 in Q3 2025.
• A 3-year average of $204683.3 and a median of $250000.0 in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 57.85% in 2025 and jumped 109.18% in 2026, its largest moves.
• Over 3 years, Cash & Equivalents stood at $194293.0 in 2024, then rose by 28.67% to $250000.0 in 2025, then changed by 0.0% to $250000.0 in 2026.
• The last three Cash & Equivalents figures came in at $250000.0 (Q2 2026), $250000.0 (Q4 2025), and $109404.0 (Q3 2025), per Business Quant data.